<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36882218</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e002864</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2022-002864</ELocationID><Abstract><AbstractText Label="BACKGROUND">Type I interferons (IFN-I) contribute to a broad range of rheumatic and musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of IFN-I pathway activation may have clinical value. Although several IFN-I pathway assays have been proposed, the exact clinical applications are unclear. We summarise the evidence on the potential clinical utility of assays measuring IFN-I pathway activation.</AbstractText><AbstractText Label="METHODS">A systematic literature review was conducted across three databases to evaluate the use of IFN-I assays in diagnosis and monitor disease activity, prognosis, response to treatment and responsiveness to change in several RMDs.</AbstractText><AbstractText Label="RESULTS">Of 366 screened, 276 studies were selected that reported the use of assays reflecting IFN-I pathway activation for disease diagnosis (n=188), assessment of disease activity (n=122), prognosis (n=20), response to treatment (n=23) and assay responsiveness (n=59). Immunoassays, quantitative PCR (qPCR) and microarrays were reported most frequently, while systemic lupus erythematosus (SLE), rheumatoid arthritis, myositis, systemic sclerosis and primary Sj&#xf6;gren's syndrome were the most studied RMDs. The literature demonstrated significant heterogeneity in techniques, analytical conditions, risk of bias and application in diseases. Inadequate study designs and technical heterogeneity were the main limitations. IFN-I pathway activation was associated with disease activity and flare occurrence in SLE, but their incremental value was uncertain. IFN-I pathway activation may predict response to IFN-I targeting therapies and may predict response to different treatments.</AbstractText><AbstractText Label="CONCLUSIONS">Evidence indicates potential clinical value of assays measuring IFN-I pathway activation in several RMDs, but assay harmonisation and clinical validation are urged. This review informs the EULAR points to consider for the measurement and reporting of IFN-I pathway assays.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Rodr&#xed;guez-Carrio</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0011-5102</Identifier><AffiliationInfo><Affiliation>Area of Immunology, University of Oviedo, Instituto de Investigaci&#xf3;n Sanitaria del Principado de Asturias (ISPA), Asturias, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Burska</LastName><ForeName>Agata</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds &amp; NIHR Leeds Biomedical Research Centre, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conaghan</LastName><ForeName>P G</ForeName><Initials>PG</Initials><Identifier Source="ORCID">0000-0002-3478-5665</Identifier><AffiliationInfo><Affiliation>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds &amp; NIHR Leeds Biomedical Research Centre, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dik</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Laboratory Medical Immunology, department of Immunology, Erasmus MC University Medical Center Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biesen</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0434-7832</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Charit&#xe9; University Medicine Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eloranta</LastName><ForeName>Maija-Leena</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavalli</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>EULAR, PARE Patient Research Partners, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boumpas</LastName><ForeName>Dimitrios T</ForeName><Initials>DT</Initials><Identifier Source="ORCID">0000-0002-9812-4671</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Crete, Medical School, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertsias</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Rheumatology-Clinical Immunology, University of Crete, Medical School, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahren-Herlenius</LastName><ForeName>Marie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0915-7245</Identifier><AffiliationInfo><Affiliation>Karolinska Institutet, Division of Rheumatology, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehwinkel</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fr&#xe9;mond</LastName><ForeName>Marie-Louise</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris Cit&#xe9;, H&#xf4;pital Necker-Enfants Malades, Immuno-H&#xe9;matologie et Rhumatologie p&#xe9;diatriques, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crow</LastName><ForeName>Mary K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Hospital for Special Surgery, Weill Cornell Medical College, Mary Kirkland Center for Lupus Research, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronnblom</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Vital</LastName><ForeName>Ed</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds &amp; NIHR Leeds Biomedical Research Centre, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Versnel</LastName><ForeName>Marjan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology, Erasmus MC University Medical Center Rotterdam, The Netherlands m.versnel@erasmusmc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C535686">Rippling muscle disease, 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009140" MajorTopicYN="Y">Musculoskeletal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">arthritis, rheumatoid</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">immune system diseases</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword></KeywordList><CoiStatement>Competing interests: MKC has received consulting fees from AstraZeneca, Bristol Meyers Squibb, Lilly and Shannon Pharmaceuticals, as well as grant/research support from Gilead. LR has received consulting fees from AstraZeneca. EV served in the speakers&#x2019; bureau of GSK, received consulting fees from AURINIA, SANDOZ, GSK, AstraZeneca, Roche and Modus, as well as grant/research support from AstraZeneca. PGC has received consultancies or speaker fees from AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Galapagos, GSK, Merck, Pfizer, Novartis and UCB.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36882218</ArticleId><ArticleId IdType="pmc">PMC10008483</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2022-002864</ArticleId><ArticleId IdType="pii">rmdopen-2022-002864</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014;14:36&#x2013;49. 10.1038/nri3581</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3581</ArticleId><ArticleId IdType="pmc">PMC4084561</ArticleId><ArticleId IdType="pubmed">24362405</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford) 2017;56:1662&#x2013;75. 10.1093/rheumatology/kew431</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew431</ArticleId><ArticleId IdType="pubmed">28122959</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 2010;12 Suppl 1:S5. 10.1186/ar2886</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2886</ArticleId><ArticleId IdType="pmc">PMC2991778</ArticleId><ArticleId IdType="pubmed">21303493</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L, Eloranta M-L. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013;25:248&#x2013;53. 10.1097/BOR.0b013e32835c7e32</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e32835c7e32</ArticleId><ArticleId IdType="pubmed">23249830</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Heijde D, Aletaha D, Carmona L, et al. . 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8&#x2013;13. 10.1136/annrheumdis-2014-206350</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206350</ArticleId><ArticleId IdType="pmc">PMC4283681</ArticleId><ArticleId IdType="pubmed">25261577</ArticleId></ArticleIdList></Reference><Reference><Citation>Burska AN, Rodr&#xed;guez-Carrio J, Biesen R, et al. . Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. RMD Open 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9990675</ArticleId><ArticleId IdType="pubmed">36863752</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel Galil SM, El-Shafey AM, Abdul-Maksoud RS, et al. . Interferon alpha gene expression and serum level association with low vitamin D levels in Egyptian female patients with systemic lupus erythematosus. Lupus 2018;27:199&#x2013;209. 10.1177/0961203317716321</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317716321</ArticleId><ArticleId IdType="pubmed">28659049</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker-Merok A, &#xd8;stli-Eilersten G, Lester S, et al. . Circulating interferon-&#x3b1;2 levels are increased in the majority of patients with systemic lupus erythematosus and are associated with disease activity and multiple cytokine activation. Lupus 2013;22:155&#x2013;63. 10.1177/0961203312468964</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203312468964</ArticleId><ArticleId IdType="pubmed">23213068</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoso-Loyo H, Atisha-Fregoso Y, N&#xfa;&#xf1;ez-Alvarez CA, et al. . Utility of interferon-&#x3b1; as a biomarker in central neuropsychiatric involvement in systemic lupus erythematosus. J Rheumatol 2012;39:504&#x2013;9. 10.3899/jrheum.110983</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.110983</ArticleId><ArticleId IdType="pubmed">22247358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, OConnell M, Allen M, et al. . Bone marrow mesenchymal stem cells from patients with SLE maintain an interferon signature during in vitro culture. Cytokine 2020;132:154725. 10.1016/j.cyto.2019.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2019.05.012</ArticleId><ArticleId IdType="pubmed">31153744</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozo L, L&#xf3;pez P, Caminal-Montero L, et al. . Anti-ribosomal P antibodies are associated with elevated circulating ifn&#x3b1; and IL-10 levels in systemic lupus erythematosus patients. Lupus 2014;23:1477&#x2013;85. 10.1177/0961203314546020</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314546020</ArticleId><ArticleId IdType="pubmed">25107939</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V, Brauner S, Larsson A, et al. . IFN-&#x3bb;1 with th17 axis cytokines and IFN-&#x3b1; define different subsets in systemic lupus erythematosus (SLE). Arthritis Res Ther 2017;19:139. 10.1186/s13075-017-1344-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1344-7</ArticleId><ArticleId IdType="pmc">PMC5471711</ArticleId><ArticleId IdType="pubmed">28619037</ArticleId></ArticleIdList></Reference><Reference><Citation>Postal M, Sinicato NA, Peli&#xe7;ari KO, et al. . Clinical and serological manifestations associated with interferon-&#x3b1; levels in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo) 2012;67:157&#x2013;62. 10.6061/clinics/2012(02)11</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2012(02)11</ArticleId><ArticleId IdType="pmc">PMC3275113</ArticleId><ArticleId IdType="pubmed">22358241</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahin D, El-Refaey AM, El-Hawary AK, et al. . Serum interferon-alpha level in first degree relatives of systemic lupus erythematosus patients: correlation with autoantibodies titers. Egyptian Journal of Medical Human Genetics 2011;12:139&#x2013;46. 10.1016/j.ejmhg.2011.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmhg.2011.06.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis R, Seif AM, McGwin G, et al. . Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 2012;21:830&#x2013;5. 10.1177/0961203312437270</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203312437270</ArticleId><ArticleId IdType="pmc">PMC3808832</ArticleId><ArticleId IdType="pubmed">22343096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye H, Wang X, Wang L, et al. . Full high-throughput sequencing analysis of differences in expression profiles of long noncoding rnas and their mechanisms of action in systemic lupus erythematosus. Arthritis Res Ther 2019;21:70. 10.1186/s13075-019-1853-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1853-7</ArticleId><ArticleId IdType="pmc">PMC6402184</ArticleId><ArticleId IdType="pubmed">30836987</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z, Huang J, He W, et al. . Serum level of eight cytokines in Han Chinese patients with systemic lupus erythematosus using multiplex fluorescent microsphere method. Cent Eur J Immunol 2014;39:228&#x2013;35. 10.5114/ceji.2014.43728</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/ceji.2014.43728</ArticleId><ArticleId IdType="pmc">PMC4440016</ArticleId><ArticleId IdType="pubmed">26155129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zecevic L, Karamehic J, Coric J, et al. . Potential immune biomarkers in diagnosis and clinical management for systemic lupus erythematosus. J Med Biochem 2018;37:163&#x2013;71. 10.1515/jomb-2017-0048</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jomb-2017-0048</ArticleId><ArticleId IdType="pmc">PMC6294097</ArticleId><ArticleId IdType="pubmed">30581353</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang H, Narain S, Sobel E, et al. . Association of anti-nucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol 2005;117:238&#x2013;50. 10.1016/j.clim.2005.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2005.07.009</ArticleId><ArticleId IdType="pubmed">16126005</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez Matilla M, Grau Garc&#xed;a E, Fern&#xe1;ndez-Llanio Comella N, et al. . Increased interferon-1&#x3b1;, interleukin-10 and BLyS concentrations as clinical activity biomarkers in systemic lupus erythematosus. Medicina Cl&#xed;nica (English Edition) 2019;153:225&#x2013;31. 10.1016/j.medcle.2019.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medcle.2019.07.003</ArticleId><ArticleId IdType="pubmed">30795903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lood C, Amisten S, Gullstrand B, et al. . Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010;116:1951&#x2013;7. 10.1182/blood-2010-03-274605</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-03-274605</ArticleId><ArticleId IdType="pubmed">20538795</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashad DI, Abdelmagid MH, Elsherif SH. MicroRNA146a expression in lupus patients with and without renal complications. J Clin Lab Anal 2012;26:35&#x2013;40. 10.1002/jcla.20501</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.20501</ArticleId><ArticleId IdType="pmc">PMC6807509</ArticleId><ArticleId IdType="pubmed">24833532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanakoudi-Tsakalidou F, Farmaki E, Tzimouli V, et al. . Simultaneous changes in serum HMGB1 and IFN-&#x3b1; levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. new therapeutic options? Lupus 2014;23:305&#x2013;12. 10.1177/0961203313519157</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313519157</ArticleId><ArticleId IdType="pubmed">24399813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Jiao Y, Zhang J, et al. . Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-&#x3b1; and TNF-&#x3b1; in systemic lupus erythematosus. Rheumatol Int 2012;32:395&#x2013;402. 10.1007/s00296-010-1636-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-010-1636-6</ArticleId><ArticleId IdType="pubmed">21120500</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal M, Tripathy R, Panda AK, et al. . Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha. Arthritis Res Ther 2014;16:R49. 10.1186/ar4479</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4479</ArticleId><ArticleId IdType="pmc">PMC3979045</ArticleId><ArticleId IdType="pubmed">24507879</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco Y, Barahona-Correa J, Monsalve DM, et al. . Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J Transl Med 2017;15:239. 10.1186/s12967-017-1345-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-017-1345-y</ArticleId><ArticleId IdType="pmc">PMC5702157</ArticleId><ArticleId IdType="pubmed">29178890</ArticleId></ArticleIdList></Reference><Reference><Citation>Robak E, Smolewski P, Wozniacka A, et al. . Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus. Eur Cytokine Netw 2004;15:222&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">15542447</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen CT, Lood C, Ostergaard O, et al. . Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med 2014;1:e000026. 10.1136/lupus-2014-000026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000026</ArticleId><ArticleId IdType="pmc">PMC4246916</ArticleId><ArticleId IdType="pubmed">25452879</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira JJ, Karrar S, Rainbow DB, et al. . The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus. Arthritis Res Ther 2018;20:152. 10.1186/s13075-018-1649-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1649-1</ArticleId><ArticleId IdType="pmc">PMC6062988</ArticleId><ArticleId IdType="pubmed">30053827</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen NJ, McAloose C, Carter J, et al. . Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment. Autoimmune Dis 2016;2016:8791629. 10.1155/2016/8791629</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/8791629</ArticleId><ArticleId IdType="pmc">PMC5225311</ArticleId><ArticleId IdType="pubmed">28116147</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen LL, van Roon JAG, Mertens JS, et al. . Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2018;77:1810&#x2013;4. 10.1136/annrheumdis-2018-213497</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213497</ArticleId><ArticleId IdType="pubmed">30185417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahadat MJ, Bodewes ILA, Maria NI, et al. . Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors? Arthritis Res Ther 2018;20:4. 10.1186/s13075-017-1501-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1501-z</ArticleId><ArticleId IdType="pmc">PMC5763828</ArticleId><ArticleId IdType="pubmed">29321042</ArticleId></ArticleIdList></Reference><Reference><Citation>al-Masri AN, Werfel T, Jakschies D, et al. . Intracellular staining of Mx proteins in cells from peripheral blood, bone marrow and skin. Mol Pathol 1997;50:9&#x2013;14. 10.1136/mp.50.1.9</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/mp.50.1.9</ArticleId><ArticleId IdType="pmc">PMC379572</ArticleId><ArticleId IdType="pubmed">9208807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirestam L, Enocsson H, Skogh T, et al. . Interferon-&#x391; coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro. Clin Exp Immunol 2017;189:83&#x2013;91. 10.1111/cei.12957</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12957</ArticleId><ArticleId IdType="pmc">PMC5461103</ArticleId><ArticleId IdType="pubmed">28257596</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg S, Eloranta ML, Cederblad B, et al. . Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001;10:484&#x2013;90. 10.1191/096120301678416042</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120301678416042</ArticleId><ArticleId IdType="pubmed">11480846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Mouries-Martin S, Dorgham K, et al. . Ultrasensitive serum interferon-&#x3b1; quantification during SLE remission identifies patients at risk for relapse. Ann Rheum Dis 2019;78:1669&#x2013;76. 10.1136/annrheumdis-2019-215571</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215571</ArticleId><ArticleId IdType="pubmed">31570366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodero MP, Decalf J, Bondet V, et al. . Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med 2017;214:1547&#x2013;55. 10.1084/jem.20161451</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20161451</ArticleId><ArticleId IdType="pmc">PMC5413335</ArticleId><ArticleId IdType="pubmed">28420733</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi SN, Feng SF, Wen YM, et al. . Serum interferon in systemic lupus erythematosus. Br J Dermatol 1987;117:155&#x2013;9. 10.1111/j.1365-2133.1987.tb04111.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.1987.tb04111.x</ArticleId><ArticleId IdType="pubmed">2443158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Kanayama Y, Negoro N, et al. . Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol
1987;70:562&#x2013;9. doi:2449306</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1542177</ArticleId><ArticleId IdType="pubmed">2449306</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lee PY, Kellner ES, et al. . Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R90. 10.1186/ar3017</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3017</ArticleId><ArticleId IdType="pmc">PMC2911874</ArticleId><ArticleId IdType="pubmed">20478071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm TR, Taddeo A, Winter O, et al. . Siglec-1-positive plasmacytoid dendritic cells (pdcs) in human peripheral blood: a semi-mature and myeloid-like subset imbalanced during protective and autoimmune responses. Clin Immunol 2016;163:42&#x2013;51. 10.1016/j.clim.2015.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2015.12.001</ArticleId><ArticleId IdType="pubmed">26674280</ArticleId></ArticleIdList></Reference><Reference><Citation>Biesen R, Demir C, Barkhudarova F, et al. . Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008;58:1136&#x2013;45. 10.1002/art.23404</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23404</ArticleId><ArticleId IdType="pubmed">18383365</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau R, Hong S, Cantarel B, et al. . Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016;165:551&#x2013;65. 10.1016/j.cell.2016.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.03.008</ArticleId><ArticleId IdType="pmc">PMC5426482</ArticleId><ArticleId IdType="pubmed">27040498</ArticleId></ArticleIdList></Reference><Reference><Citation>Flint SM, Jovanovic V, Teo BW, et al. . Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases. RMD Open 2016;2:e000183. 10.1136/rmdopen-2015-000183</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2015-000183</ArticleId><ArticleId IdType="pmc">PMC4879345</ArticleId><ArticleId IdType="pubmed">27252891</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay M, Oswald M, Sanchez-Guerrero J, et al. . Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection. Lupus Sci Med 2016;3:e000159. 10.1136/lupus-2016-000159</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000159</ArticleId><ArticleId IdType="pmc">PMC5133406</ArticleId><ArticleId IdType="pubmed">27933197</ArticleId></ArticleIdList></Reference><Reference><Citation>Olferiev M, Jacek E, Kirou KA, et al. . Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus. Clin Immunol 2016;172:34&#x2013;43. 10.1016/j.clim.2016.08.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.08.018</ArticleId><ArticleId IdType="pubmed">27576056</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiche L, Jourde-Chiche N, Whalen E, et al. . Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014;66:1583&#x2013;95. 10.1002/art.38628</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38628</ArticleId><ArticleId IdType="pmc">PMC4157826</ArticleId><ArticleId IdType="pubmed">24644022</ArticleId></ArticleIdList></Reference><Reference><Citation>Assassi S, Mayes MD, Arnett FC, et al. . Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 2010;62:589&#x2013;98. 10.1002/art.27224</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27224</ArticleId><ArticleId IdType="pmc">PMC2879587</ArticleId><ArticleId IdType="pubmed">20112391</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Bauer JW, Slattery CA, et al. . An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13:59&#x2013;68. 10.2119/2006-00085.Baechler</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/2006-00085.Baechler</ArticleId><ArticleId IdType="pmc">PMC1869622</ArticleId><ArticleId IdType="pubmed">17515957</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Batliwalla FM, Karypis G, et al. . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610&#x2013;5. 10.1073/pnas.0337679100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0337679100</ArticleId><ArticleId IdType="pmc">PMC151388</ArticleId><ArticleId IdType="pubmed">12604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker AM, Dao KH, Han BK, et al. . SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One 2013;8:e67003. 10.1371/journal.pone.0067003</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067003</ArticleId><ArticleId IdType="pmc">PMC3691135</ArticleId><ArticleId IdType="pubmed">23826184</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey-Rao R, Sinha AA. Genome-wide transcriptional profiling of chronic cutaneous lupus erythematosus (CCLE) peripheral blood identifies systemic alterations relevant to the skin manifestation. Genomics 2015;105:90&#x2013;100. 10.1016/j.ygeno.2014.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2014.11.004</ArticleId><ArticleId IdType="pubmed">25451738</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgs BW, Liu Z, White B, et al. . Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029&#x2013;36. 10.1136/ard.2011.150326</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2011.150326</ArticleId><ArticleId IdType="pubmed">21803750</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman RW, Merrill JT, Alarc&#xf3;n-Riquelme MME, et al. . Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab. Arthritis Rheumatol 2017;69:643&#x2013;54. 10.1002/art.39950</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39950</ArticleId><ArticleId IdType="pmc">PMC6585752</ArticleId><ArticleId IdType="pubmed">27723281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyogoku C, Smiljanovic B, Gr&#xfc;n JR, et al. . Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference? PLoS ONE 2013;8:e83776. 10.1371/journal.pone.0083776</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0083776</ArticleId><ArticleId IdType="pmc">PMC3877094</ArticleId><ArticleId IdType="pubmed">24391825</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugar PL, Love C, Grammer AC, et al. . Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus. PLoS One 2012;7:e44362. 10.1371/journal.pone.0044362</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044362</ArticleId><ArticleId IdType="pmc">PMC3448624</ArticleId><ArticleId IdType="pubmed">23028528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S, Pang H, Gu Y-Y, et al. . Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1. Rheumatology (Oxford) 2003;42:1155&#x2013;63. 10.1093/rheumatology/keg315</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keg315</ArticleId><ArticleId IdType="pubmed">12777642</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgs BW, Zhu W, Richman L, et al. . Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis 2012;15:25&#x2013;35. 10.1111/j.1756-185X.2011.01654.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1756-185X.2011.01654.x</ArticleId><ArticleId IdType="pubmed">22324944</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauwerys BR, Hachulla E, Spertini F, et al. . Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon &#x3b1;-kinoid. Arthritis Rheum 2013;65:447&#x2013;56. 10.1002/art.37785</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37785</ArticleId><ArticleId IdType="pubmed">23203821</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Richman L, Higgs BW, et al. . Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785&#x2013;96. 10.1002/art.24557</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24557</ArticleId><ArticleId IdType="pubmed">19479852</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Sanchez C, Barbarroja N, Messineo S, et al. . Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis 2015;74:1441&#x2013;9. 10.1136/annrheumdis-2013-204600</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204600</ArticleId><ArticleId IdType="pubmed">24618261</ArticleId></ArticleIdList></Reference><Reference><Citation>Smiljanovic B, Gr&#xfc;n JR, Biesen R, et al. . The multifaceted balance of TNF-&#x3b1; and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J Mol Med (Berl) 2012;90:1295&#x2013;309. 10.1007/s00109-012-0907-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-012-0907-y</ArticleId><ArticleId IdType="pubmed">22610275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H, Mi W, Luo H, et al. . Whole-genome transcription and DNA methylation analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus. Arthritis Res Ther 2016;18:162. 10.1186/s13075-016-1050-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1050-x</ArticleId><ArticleId IdType="pmc">PMC4942934</ArticleId><ArticleId IdType="pubmed">27412348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy WP, Maciuca R, Wolslegel K, et al. . Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci Med 2015;2:e000080. 10.1136/lupus-2014-000080</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000080</ArticleId><ArticleId IdType="pmc">PMC4379884</ArticleId><ArticleId IdType="pubmed">25861459</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsuda A, Wakui H, Iwamoto K, et al. . Up-regulated expression of toll-like receptors mrnas in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008;152:482&#x2013;7. 10.1111/j.1365-2249.2008.03646.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2008.03646.x</ArticleId><ArticleId IdType="pmc">PMC2453201</ArticleId><ArticleId IdType="pubmed">18373699</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Song L, Fan Y, et al. . Down-Regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Immunol 2009;133:422&#x2013;7. 10.1016/j.clim.2009.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2009.08.014</ArticleId><ArticleId IdType="pubmed">19748832</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y, Ma H, Ye Z, et al. . Interferon-Stimulated gene 15 expression in systemic lupus erythematosus. Z Rheumatol 2018;77:256&#x2013;62. 10.1007/s00393-017-0274-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00393-017-0274-8</ArticleId><ArticleId IdType="pubmed">28204879</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokland SLM, van den Hoogen LL, Leijten EFA, et al. . Increased expression of Fas on group 2 and 3 innate lymphoid cells is associated with an interferon signature in systemic lupus erythematosus and Sj&#xf6;gren&#x2019;s syndrome. Rheumatology (Oxford) 2019;58:1740&#x2013;5. 10.1093/rheumatology/kez116</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez116</ArticleId><ArticleId IdType="pubmed">31220315</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunstein I, Klein R, Okawa J, et al. . The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol 2012;166:971&#x2013;5. 10.1111/j.1365-2133.2012.10825.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2012.10825.x</ArticleId><ArticleId IdType="pmc">PMC3336025</ArticleId><ArticleId IdType="pubmed">22242767</ArticleId></ArticleIdList></Reference><Reference><Citation>Brkic Z, Corneth OBJ, van Helden-Meeuwsen CG, et al. . T-Helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus? Arthritis Res Ther 2014;16:R62. 10.1186/ar4499</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4499</ArticleId><ArticleId IdType="pmc">PMC4060204</ArticleId><ArticleId IdType="pubmed">24598455</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong TD, L&#xfc;bbers J, Turk S, et al. . The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes. Arthritis Res Ther 2016;18:165. 10.1186/s13075-016-1065-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1065-3</ArticleId><ArticleId IdType="pmc">PMC4944477</ArticleId><ArticleId IdType="pubmed">27411379</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Gutierrez PR, Ceribelli A, Satoh M, et al. . Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus. Arthritis Res Ther 2014;16:R20. 10.1186/ar4448</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4448</ArticleId><ArticleId IdType="pmc">PMC3978614</ArticleId><ArticleId IdType="pubmed">24451065</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Gutierrez PR, Ceribelli A, Satoh M, et al. . Positive correlation of STAT1 and miR-146a with anemia in patients with systemic lupus erythematosus. J Clin Immunol 2014;34:171&#x2013;80. 10.1007/s10875-013-9973-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-013-9973-3</ArticleId><ArticleId IdType="pmc">PMC3943692</ArticleId><ArticleId IdType="pubmed">24292724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekholm L, Kahlenberg JM, Barbasso Helmers S, et al. . Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis. Rheumatology (Oxford) 2016;55:1987&#x2013;92. 10.1093/rheumatology/kew288</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew288</ArticleId><ArticleId IdType="pmc">PMC5088625</ArticleId><ArticleId IdType="pubmed">27498356</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sherbiny YM, Psarras A, Md Yusof MY, et al. . A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. Sci Rep 2018;8:5793. 10.1038/s41598-018-24198-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-24198-1</ArticleId><ArticleId IdType="pmc">PMC5895784</ArticleId><ArticleId IdType="pubmed">29643425</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Chen W, Xiao L, et al. . Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus. Lupus 2017;26:62&#x2013;72. 10.1177/0961203316651738</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316651738</ArticleId><ArticleId IdType="pmc">PMC5124426</ArticleId><ArticleId IdType="pubmed">27230555</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Huang J, Liu Y, et al. . Identification of interferon-inducible genes as diagnostic biomarker for systemic lupus erythematosus. Clin Rheumatol 2015;34:71&#x2013;9. 10.1007/s10067-014-2799-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-014-2799-4</ArticleId><ArticleId IdType="pubmed">25344775</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Q, Chen X, Cui H, et al. . Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther 2008;10:R112. 10.1186/ar2510</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2510</ArticleId><ArticleId IdType="pmc">PMC2592795</ArticleId><ArticleId IdType="pubmed">18793417</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Werth VP, Merola JF, et al. . Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest 2019;129:1359&#x2013;71. 10.1172/JCI124466</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124466</ArticleId><ArticleId IdType="pmc">PMC6391094</ArticleId><ArticleId IdType="pubmed">30645203</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, Fan W, Jensen MA, et al. . Single-cell gene expression patterns in lupus monocytes independently indicate disease activity, interferon and therapy. Lupus Sci Med 2017;4:e000202. 10.1136/lupus-2016-000202</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000202</ArticleId><ArticleId IdType="pmc">PMC5724340</ArticleId><ArticleId IdType="pubmed">29238602</ArticleId></ArticleIdList></Reference><Reference><Citation>Landolt-Marticorena C, Bonventi G, Lubovich A, et al. . Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009;68:1440&#x2013;6. 10.1136/ard.2008.093146</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.093146</ArticleId><ArticleId IdType="pubmed">18772188</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Liu J, Hao S, et al. . Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity. Clin Rheumatol 2018;37:2675&#x2013;84. 10.1007/s10067-018-4138-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4138-7</ArticleId><ArticleId IdType="pubmed">29774490</ArticleId></ArticleIdList></Reference><Reference><Citation>Md Yusof MY, Psarras A, El-Sherbiny YM, et al. . Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis 2018;77:1432&#x2013;9. 10.1136/annrheumdis-2018-213386</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213386</ArticleId><ArticleId IdType="pmc">PMC6161671</ArticleId><ArticleId IdType="pubmed">29929956</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds JA, Briggs TA, Rice GI, et al. . Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. Arthritis Res Ther 2019;21:147. 10.1186/s13075-019-1929-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1929-4</ArticleId><ArticleId IdType="pmc">PMC6567906</ArticleId><ArticleId IdType="pubmed">31200750</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Carrio J, L&#xf3;pez P, Alperi-L&#xf3;pez M, et al. . Irf4 and irgs delineate clinically relevant gene expression signatures in systemic lupus erythematosus and rheumatoid arthritis. Front Immunol 2018;9:3085. 10.3389/fimmu.2018.03085</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.03085</ArticleId><ArticleId IdType="pmc">PMC6330328</ArticleId><ArticleId IdType="pubmed">30666255</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, Gu Y, Zhang M, et al. . Increased expression of the type I interferon-inducible gene, lymphocyte antigen 6 complex locus E, in peripheral blood cells is predictive of lupus activity in a large cohort of Chinese lupus patients. Lupus 2008;17:805&#x2013;13. 10.1177/0961203308089694</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203308089694</ArticleId><ArticleId IdType="pubmed">18755862</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyd&#xe9;n H, Lood C, Gullstrand B, et al. . Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus. RMD Open 2017;3:e000508. 10.1136/rmdopen-2017-000508</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2017-000508</ArticleId><ArticleId IdType="pmc">PMC5663269</ArticleId><ArticleId IdType="pubmed">29119007</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen LL, Fritsch-Stork RDE, Versnel MA, et al. . Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use. Ann Rheum Dis 2016;75:e81. 10.1136/annrheumdis-2016-210485</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-210485</ArticleId><ArticleId IdType="pubmed">27689737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodewes ILA, Huijser E, van Helden-Meeuwsen CG, et al. . TBK1: a key regulator and potential treatment target for interferon positive sj&#xf6;gren&#x2019;s syndrome, systemic lupus erythematosus and systemic sclerosis. J Autoimmun 2018;91:97&#x2013;102. 10.1016/j.jaut.2018.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.02.001</ArticleId><ArticleId IdType="pubmed">29673738</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey KA, Guo X, Smith MA, et al. . Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med 2018;5:e000286. 10.1136/lupus-2018-000286</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000286</ArticleId><ArticleId IdType="pmc">PMC6257383</ArticleId><ArticleId IdType="pubmed">30538817</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Gutierrez PR, Ceribelli A, Satoh M, et al. . Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Arthritis Res Ther 2014;16:R23. 10.1186/ar4451</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4451</ArticleId><ArticleId IdType="pmc">PMC3978465</ArticleId><ArticleId IdType="pubmed">24460726</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Wu H, Grossman JM, et al. . Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951&#x2013;62. 10.1002/art.22044</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22044</ArticleId><ArticleId IdType="pubmed">16947629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirou KA, Lee C, George S, et al. . Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491&#x2013;503. 10.1002/art.21031</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21031</ArticleId><ArticleId IdType="pubmed">15880830</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PY, Li Y, Richards HB, et al. . Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007;56:3759&#x2013;69. 10.1002/art.23035</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23035</ArticleId><ArticleId IdType="pubmed">17968925</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q-Z, Zhou J, Lian Y, et al. . Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol 2010;159:281&#x2013;91. 10.1111/j.1365-2249.2009.04057.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2009.04057.x</ArticleId><ArticleId IdType="pmc">PMC2819494</ArticleId><ArticleId IdType="pubmed">19968664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellner ES, Lee PY, Li Y, et al. . Endogenous type-I interferon activity is not associated with depression or fatigue in systemic lupus erythematosus. J Neuroimmunol 2010;223:13&#x2013;9. 10.1016/j.jneuroim.2010.03.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2010.03.018</ArticleId><ArticleId IdType="pmc">PMC3580233</ArticleId><ArticleId IdType="pubmed">20416954</ArticleId></ArticleIdList></Reference><Reference><Citation>Wither J, Johnson SR, Liu T, et al. . Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis. Arthritis Res Ther 2017;19:41. 10.1186/s13075-017-1243-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1243-y</ArticleId><ArticleId IdType="pmc">PMC5331647</ArticleId><ArticleId IdType="pubmed">28245862</ArticleId></ArticleIdList></Reference><Reference><Citation>Coit P, Jeffries M, Altorok N, et al. . Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in na&#xef;ve CD4+ T cells from lupus patients. J Autoimmun 2013;43:78&#x2013;84. 10.1016/j.jaut.2013.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2013.04.003</ArticleId><ArticleId IdType="pmc">PMC3790645</ArticleId><ArticleId IdType="pubmed">23623029</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph S, George NI, Green-Knox B, et al. . Epigenome-wide association study of peripheral blood mononuclear cells in systemic lupus erythematosus: identifying DNA methylation signatures associated with interferon-related genes based on ethnicity and SLEDAI. J Autoimmun 2019;96:147&#x2013;57. 10.1016/j.jaut.2018.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.09.007</ArticleId><ArticleId IdType="pubmed">30301579</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung KS, Chung BH-Y, Choufani S, et al. . Genome-wide DNA methylation analysis of chinese patients with systemic lupus erythematosus identified hypomethylation in genes related to the type I interferon pathway. PLoS One 2017;12:e0169553. 10.1371/journal.pone.0169553</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0169553</ArticleId><ArticleId IdType="pmc">PMC5234836</ArticleId><ArticleId IdType="pubmed">28085900</ArticleId></ArticleIdList></Reference><Reference><Citation>Absher DM, Li X, Waite LL, et al. . Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet 2013;9:e1003678. 10.1371/journal.pgen.1003678</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1003678</ArticleId><ArticleId IdType="pmc">PMC3738443</ArticleId><ArticleId IdType="pubmed">23950730</ArticleId></ArticleIdList></Reference><Reference><Citation>Coit P, Yalavarthi S, Ognenovski M, et al. . Epigenome profiling reveals significant DNA demethylation of interferon signature genes in lupus neutrophils. J Autoimmun 2015;58:59&#x2013;66. 10.1016/j.jaut.2015.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.01.004</ArticleId><ArticleId IdType="pmc">PMC4363276</ArticleId><ArticleId IdType="pubmed">25638528</ArticleId></ArticleIdList></Reference><Reference><Citation>Imgenberg-Kreuz J, Alml&#xf6;f JC, Leonard D, et al. . Shared and unique patterns of DNA methylation in systemic lupus erythematosus and primary sj&#xf6;gren&#x2019;s syndrome. Front Immunol 2019;10:1686. 10.3389/fimmu.2019.01686</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01686</ArticleId><ArticleId IdType="pmc">PMC6688520</ArticleId><ArticleId IdType="pubmed">31428085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulff-M&#xf8;ller CJ, Asmar F, Liu Y, et al. . Twin DNA methylation profiling reveals flare-dependent interferon signature and B cell promoter hypermethylation in systemic lupus erythematosus. Arthritis Rheumatol 2018;70:878&#x2013;90. 10.1002/art.40422</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40422</ArticleId><ArticleId IdType="pubmed">29361205</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeding E, Coit P, Yalavarthi S, et al. . Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils. Clin Immunol 2018;196:110&#x2013;6. 10.1016/j.clim.2018.11.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2018.11.011</ArticleId><ArticleId IdType="pmc">PMC6413498</ArticleId><ArticleId IdType="pubmed">30471352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Zhou Y, Zhu B, et al. . IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus. Ann Rheum Dis 2016;75:1998&#x2013;2006. 10.1136/annrheumdis-2015-208410</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208410</ArticleId><ArticleId IdType="pmc">PMC4955646</ArticleId><ArticleId IdType="pubmed">26787370</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade D, Kim M, Blanco LP, et al. . Interferon-&#x391; and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol 2015;67:977&#x2013;87. 10.1002/art.39029</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39029</ArticleId><ArticleId IdType="pmc">PMC4380868</ArticleId><ArticleId IdType="pubmed">25603823</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua J, Kirou K, Lee C, et al. . Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906&#x2013;16. 10.1002/art.21890</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21890</ArticleId><ArticleId IdType="pubmed">16736505</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers EC, Zhao W, Lewis EE, et al. . Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012;7:e37000. 10.1371/journal.pone.0037000</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037000</ArticleId><ArticleId IdType="pmc">PMC3351452</ArticleId><ArticleId IdType="pubmed">22606325</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold TB, Rivera TL, Buyon JP, et al. . Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/ro-positive mothers of children with neonatal lupus. Arthritis Rheum 2008;58:541&#x2013;6. 10.1002/art.23191</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23191</ArticleId><ArticleId IdType="pmc">PMC2755051</ArticleId><ArticleId IdType="pubmed">18240214</ArticleId></ArticleIdList></Reference><Reference><Citation>Weckerle CE, Mangale D, Franek BS, et al. . Large-Scale analysis of tumor necrosis factor &#x3b1; levels in systemic lupus erythematosus. Arthritis Rheum 2012;64:2947&#x2013;52. 10.1002/art.34483</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34483</ArticleId><ArticleId IdType="pmc">PMC3396783</ArticleId><ArticleId IdType="pubmed">22488302</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold TB, Hua J, Lehman TJA, et al. . High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492&#x2013;502. 10.1038/sj.gene.6364408</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gene.6364408</ArticleId><ArticleId IdType="pmc">PMC2702174</ArticleId><ArticleId IdType="pubmed">17581626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirou KA, Lee C, George S, et al. . Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958&#x2013;67. 10.1002/art.20798</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20798</ArticleId><ArticleId IdType="pubmed">15593221</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas PS, Pawaria S, Maers K, et al. . Complement component c5a permits the co-existence of pathogenic th17 cells and type I interferon in lupus. Cytokine 2013;63:248. 10.1016/j.cyto.2013.06.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2013.06.026</ArticleId><ArticleId IdType="pubmed">25149466</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;era MC, Cardarelli PM, Preston BT, et al. . Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692&#x2013;7. 10.1136/ard.2004.033753</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.033753</ArticleId><ArticleId IdType="pmc">PMC1755300</ArticleId><ArticleId IdType="pubmed">15843451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y, Park J, Takamatsu H, et al. . Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. Ann Rheum Dis 2018;77:1507&#x2013;15. 10.1136/annrheumdis-2018-212988</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-212988</ArticleId><ArticleId IdType="pmc">PMC6161667</ArticleId><ArticleId IdType="pubmed">29945921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackovic V, Boreck&#xfd; L, Rovensk&#xfd; J, et al. . Periodicity of interferon appearance in serum of patients with systemic lupus erythematosus. Arthritis Rheum 1984;27:597&#x2013;8. 10.1002/art.1780270523</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780270523</ArticleId><ArticleId IdType="pubmed">6202304</ArticleId></ArticleIdList></Reference><Reference><Citation>Preble OT, Black RJ, Friedman RM, et al. . Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982;216:429&#x2013;31. 10.1126/science.6176024</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6176024</ArticleId><ArticleId IdType="pubmed">6176024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hervier B, Beziat V, Haroche J, et al. . Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-&#x3b3; production in patients with active disease. Arthritis Rheum 2011;63:1698&#x2013;706. 10.1002/art.30313</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30313</ArticleId><ArticleId IdType="pubmed">21370226</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooks JJ, Moutsopoulos HM, Geis SA, et al. . Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5&#x2013;8. 10.1056/NEJM197907053010102</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197907053010102</ArticleId><ArticleId IdType="pubmed">449915</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesario TC, Andrews BS, Martin DA, et al. . Interferon in synovial fluid and serum of patients with rheumatic disease. J Rheumatol 1983;10:647&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">6194296</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooks JJ, Jordan GW, Cupps T, et al. . Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum 1982;25:396&#x2013;400. 10.1002/art.1780250406</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780250406</ArticleId><ArticleId IdType="pubmed">6176247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25:401&#x2013;6. 10.1002/art.1780250407</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780250407</ArticleId><ArticleId IdType="pubmed">6176248</ArticleId></ArticleIdList></Reference><Reference><Citation>Weix J, H&#xe4;upl T, Raio L, et al. . The physiologic increase in expression of some type I IFN-inducible genes during pregnancy is not associated with improved disease activity in pregnant patients with rheumatoid arthritis. Transl Res 2013;161:505&#x2013;12. 10.1016/j.trsl.2013.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2013.02.007</ArticleId><ArticleId IdType="pubmed">23507374</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Carrio J, de Paz B, L&#xf3;pez P, et al. . IFN&#x3b1; serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients. PLoS One 2014;9:e86069. 10.1371/journal.pone.0086069</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0086069</ArticleId><ArticleId IdType="pmc">PMC3897639</ArticleId><ArticleId IdType="pubmed">24465874</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore L, Pennesi M, Saletta S, et al. . Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994;12:561&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7531125</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe5;ve U, Nordmark G, L&#xf6;vgren T, et al. . Activation of the type I interferon system in primary Sj&#xf6;gren&#x2019;s syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185&#x2013;95. 10.1002/art.20998</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20998</ArticleId><ArticleId IdType="pubmed">15818675</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong KY, Boey ML, Koh WH, et al. . Cytokine concentrations in the synovial fluid and plasma of rheumatoid arthritis patients: correlation with bony erosions. Clin Exp Rheumatol 1994;12:55&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8162643</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiozawa S, Chihara K, Shiozawa K, et al. . A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients. Clin Exp Immunol 1986;66:77&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1542641</ArticleId><ArticleId IdType="pubmed">3802576</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett L, Palucka AK, Arce E, et al. . Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711&#x2013;23. 10.1084/jem.20021553</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021553</ArticleId><ArticleId IdType="pmc">PMC2193846</ArticleId><ArticleId IdType="pubmed">12642603</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynier F, Petit F, Paye M, et al. . Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis. PLoS One 2011;6:e24828. 10.1371/journal.pone.0024828</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024828</ArticleId><ArticleId IdType="pmc">PMC3197194</ArticleId><ArticleId IdType="pubmed">22043277</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Pouw Kraan TCTM, Wijbrandts CA, van Baarsen LGM, et al. . Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66:1008&#x2013;14. 10.1136/ard.2006.063412</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.063412</ArticleId><ArticleId IdType="pmc">PMC1954704</ArticleId><ArticleId IdType="pubmed">17223656</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q-Z, Karp DR, Quan J, et al. . Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011;13:R38. 10.1186/ar3271</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3271</ArticleId><ArticleId IdType="pmc">PMC3132017</ArticleId><ArticleId IdType="pubmed">21366908</ArticleId></ArticleIdList></Reference><Reference><Citation>Casta&#xf1;eda-Delgado JE, Basti&#xe1;n-Hernandez Y, Macias-Segura N, et al. . Type I interferon gene response is increased in early and established rheumatoid arthritis and correlates with autoantibody production. Front Immunol 2017;8:285. 10.3389/fimmu.2017.00285</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00285</ArticleId><ArticleId IdType="pmc">PMC5357778</ArticleId><ArticleId IdType="pubmed">28373872</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong TD, Vosslamber S, Mantel E, et al. . Physiological evidence for diversification of ifn&#x3b1;- and ifn&#x3b2;-mediated response programs in different autoimmune diseases. Arthritis Res Ther 2016;18:49. 10.1186/s13075-016-0946-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-0946-9</ArticleId><ArticleId IdType="pmc">PMC4756531</ArticleId><ArticleId IdType="pubmed">26882897</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Carrio J, Alperi-L&#xf3;pez M, L&#xf3;pez P, et al. . Heterogeneity of the type I interferon signature in rheumatoid arthritis: A potential limitation for its use as A clinical biomarker. Front Immunol 2017;8:2007. 10.3389/fimmu.2017.02007</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.02007</ArticleId><ArticleId IdType="pmc">PMC5775969</ArticleId><ArticleId IdType="pubmed">29387065</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooles FAH, Anderson AE, Lendrem DW, et al. . The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy. J Allergy Clin Immunol 2018;141:445&#x2013;8. 10.1016/j.jaci.2017.08.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2017.08.026</ArticleId><ArticleId IdType="pmc">PMC5751729</ArticleId><ArticleId IdType="pubmed">28987811</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright HL, Thomas HB, Moots RJ, et al. . Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to tnfi therapy. Rheumatology (Oxford) 2015;54:188&#x2013;93. 10.1093/rheumatology/keu299</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu299</ArticleId><ArticleId IdType="pubmed">25125592</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavragani CP, La DT, Stohl W, et al. . Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: A post hoc analysis of A predominantly hispanic cohort. Arthritis Rheum 2010;62:392&#x2013;401. 10.1002/art.27226</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27226</ArticleId><ArticleId IdType="pmc">PMC2821991</ArticleId><ArticleId IdType="pubmed">20112385</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertzog PJ, Emery P, Cheetham BF, et al. . Interferons in rheumatoid arthritis: alterations in production and response related to disease activity. Clin Immunol Immunopathol 1988;48:192&#x2013;201. 10.1016/0090-1229(88)90083-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-1229(88)90083-9</ArticleId><ArticleId IdType="pubmed">2455616</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvin AM, Miller JJ. Acid labile alpha-interferon in sera and synovial fluids from patients with juvenile arthritis. Arthritis Rheum 1984;27:582&#x2013;5. 10.1002/art.1780270517</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780270517</ArticleId><ArticleId IdType="pubmed">6721889</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard RPE, Abdulahad WH, Bootsma H, et al. . Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren&#x2019;s syndrome. Ann Rheum Dis 2013;72:2048&#x2013;50. 10.1136/annrheumdis-2013-203447</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-203447</ArticleId><ArticleId IdType="pubmed">23864239</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L, Zhang Z, Yu C, et al. . Association between IFN-alpha and primary Sjogren&#x2019;s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:e12&#x2013;8. 10.1016/j.tripleo.2008.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tripleo.2008.09.015</ArticleId><ArticleId IdType="pubmed">19101478</ArticleId></ArticleIdList></Reference><Reference><Citation>Imgenberg-Kreuz J, Sandling JK, Bj&#xf6;rk A, et al. . Transcription profiling of peripheral B cells in antibody-positive primary Sj&#xf6;gren&#x2019;s syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature. Scand J Immunol 2018;87:e12662. 10.1111/sji.12662</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12662</ArticleId><ArticleId IdType="pubmed">29655283</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, et al. . Systemic increase in type I interferon activity in Sj&#xf6;gren&#x2019;s syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024&#x2013;33. 10.1002/eji.200738008</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200738008</ArticleId><ArticleId IdType="pubmed">18581327</ArticleId></ArticleIdList></Reference><Reference><Citation>Alunno A, Caneparo V, Bistoni O, et al. . FRI0024 Interferon gamma-inducible protein 16 (IFI16) in rheumatoid arthritis: a novel biomarker for pulmonary involvement? Ann Rheum Dis 2015;74:427. 10.1136/annrheumdis-2015-eular.1811</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-eular.1811</ArticleId></ArticleIdList></Reference><Reference><Citation>Maria NI, Brkic Z, Waris M, et al. . Mxa as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren&#x2019;s syndrome. Ann Rheum Dis 2014;73:1052&#x2013;9. 10.1136/annrheumdis-2012-202552</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202552</ArticleId><ArticleId IdType="pmc">PMC4033122</ArticleId><ArticleId IdType="pubmed">23831963</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose T, Szelinski F, Lisney A, et al. . SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sj&#xf6;gren&#x2019;s syndrome. RMD Open 2016;2:e000292. 10.1136/rmdopen-2016-000292</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2016-000292</ArticleId><ArticleId IdType="pmc">PMC5237743</ArticleId><ArticleId IdType="pubmed">28123773</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiozawa S, Shiozawa K, Shimizu S, et al. . Immunoreactive circulating alpha-interferon is low in Sj&#xf6;gren&#x2019;s syndrome. Br J Rheumatol 1990;29:50&#x2013;2. 10.1093/rheumatology/29.1.50</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/29.1.50</ArticleId><ArticleId IdType="pubmed">2306573</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamian ES, Leon JM, Lessard CJ, et al. . Peripheral blood gene expression profiling in Sj&#xf6;gren&#x2019;s syndrome. Genes Immun 2009;10:285&#x2013;96. 10.1038/gene.2009.20</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gene.2009.20</ArticleId><ArticleId IdType="pmc">PMC3273959</ArticleId><ArticleId IdType="pubmed">19404300</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimoto O, Sawada J, Shimoyama K, et al. . Activation of the interferon pathway in peripheral blood of patients with Sjogren&#x2019;s syndrome. J Rheumatol 2011;38:310&#x2013;6. 10.3899/jrheum.100486</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.100486</ArticleId><ArticleId IdType="pubmed">21078725</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodewes ILA, Gottenberg J-E, van Helden-Meeuwsen CG, et al. . Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj&#xf6;gren&#x2019;s syndrome in the JOQUER randomized trial. Rheumatology (Oxford) 2020;59:107&#x2013;11. 10.1093/rheumatology/kez242</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez242</ArticleId><ArticleId IdType="pmc">PMC6909893</ArticleId><ArticleId IdType="pubmed">31237947</ArticleId></ArticleIdList></Reference><Reference><Citation>Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. . Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren&#x2019;s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013;72:728&#x2013;35. 10.1136/annrheumdis-2012-201381</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201381</ArticleId><ArticleId IdType="pmc">PMC3618683</ArticleId><ArticleId IdType="pubmed">22736090</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies R, Sarkar I, Hammenfors D, et al. . Single cell based phosphorylation profiling identifies alterations in toll-like receptor 7 and 9 signaling in patients with primary sj&#xf6;gren&#x2019;s syndrome. Front Immunol 2019;10:281. 10.3389/fimmu.2019.00281</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00281</ArticleId><ArticleId IdType="pmc">PMC6393381</ArticleId><ArticleId IdType="pubmed">30846988</ArticleId></ArticleIdList></Reference><Reference><Citation>Nezos A, Gravani F, Tassidou A, et al. . Type I and II interferon signatures in sjogren&#x2019;s syndrome pathogenesis: contributions in distinct clinical phenotypes and sjogren&#x2019;s related lymphomagenesis. J Autoimmun 2015;63:47&#x2013;58. 10.1016/j.jaut.2015.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.07.002</ArticleId><ArticleId IdType="pmc">PMC4564326</ArticleId><ArticleId IdType="pubmed">26183766</ArticleId></ArticleIdList></Reference><Reference><Citation>Altorok N, Coit P, Hughes T, et al. . Genome-Wide DNA methylation patterns in naive CD4+ T cells from patients with primary Sj&#xf6;gren&#x2019;s syndrome. Arthritis Rheumatol 2014;66:731&#x2013;9. 10.1002/art.38264</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38264</ArticleId><ArticleId IdType="pmc">PMC4009982</ArticleId><ArticleId IdType="pubmed">24574234</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavragani CP, Niewold TB, Moutsopoulos NM, et al. . Augmented interferon-alpha pathway activation in patients with Sj&#xf6;gren&#x2019;s syndrome treated with etanercept. Arthritis Rheum 2007;56:3995&#x2013;4004. 10.1002/art.23062</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23062</ArticleId><ArticleId IdType="pmc">PMC2737264</ArticleId><ArticleId IdType="pubmed">18050196</ArticleId></ArticleIdList></Reference><Reference><Citation>Eloranta M-L, Franck-Larsson K, L&#xf6;vgren T, et al. . Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010;69:1396&#x2013;402. 10.1136/ard.2009.121400</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.121400</ArticleId><ArticleId IdType="pubmed">20472592</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Higgs BW, Bay-Jensen AC, et al. . Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mab, anifrolumab, in adult patients with systemic sclerosis. J Invest Dermatol 2015;135:2402&#x2013;9. 10.1038/jid.2015.188</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2015.188</ArticleId><ArticleId IdType="pubmed">25993119</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariotti B, Servaas NH, Rossato M, et al. . The long non-coding RNA NRIR drives IFN-response in monocytes: implication for systemic sclerosis. Front Immunol 2019;10:100. 10.3389/fimmu.2019.00100</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00100</ArticleId><ArticleId IdType="pmc">PMC6371048</ArticleId><ArticleId IdType="pubmed">30804934</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Mayes MD, Tan FK, et al. . Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum 2013;65:226&#x2013;35. 10.1002/art.37742</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37742</ArticleId><ArticleId IdType="pmc">PMC3687352</ArticleId><ArticleId IdType="pubmed">23055137</ArticleId></ArticleIdList></Reference><Reference><Citation>York MR, Nagai T, Mangini AJ, et al. . A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll-like receptor agonists. Arthritis Rheum 2007;56:1010&#x2013;20. 10.1002/art.22382</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22382</ArticleId><ArticleId IdType="pubmed">17328080</ArticleId></ArticleIdList></Reference><Reference><Citation>Assassi S, Wang X, Chen G, et al. . Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. Ann Rheum Dis 2019;78:1371&#x2013;8. 10.1136/annrheumdis-2019-215770</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215770</ArticleId><ArticleId IdType="pmc">PMC7167108</ArticleId><ArticleId IdType="pubmed">31391177</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos CL, van Baarsen LGM, Timmer TCG, et al. . Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes Immun 2009;10:210&#x2013;8. 10.1038/gene.2008.98</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gene.2008.98</ArticleId><ArticleId IdType="pubmed">19129850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan FK, Zhou X, Mayes MD, et al. . Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006;45:694&#x2013;702. 10.1093/rheumatology/kei244</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kei244</ArticleId><ArticleId IdType="pubmed">16418202</ArticleId></ArticleIdList></Reference><Reference><Citation>Christmann RB, Hayes E, Pendergrass S, et al. . Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum 2011;63:1718&#x2013;28. 10.1002/art.30318</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30318</ArticleId><ArticleId IdType="pmc">PMC4030759</ArticleId><ArticleId IdType="pubmed">21425123</ArticleId></ArticleIdList></Reference><Reference><Citation>Air&#xf2; P, Ghidini C, Zanotti C, et al. . Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis. J Rheumatol 2008;35:2192&#x2013;200. 10.3899/jrheum.080418</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.080418</ArticleId><ArticleId IdType="pubmed">18843779</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira DB, Almeida GM de F, Guedes ACM, et al. . Basal activation of type I interferons (alpha2 and beta) and 2&#x2019; &#x2019;'OAS genes: insights into differential expression profiles of interferon system components in systemic sclerosis. Int J Rheumatol 2011;2011:275617. 10.1155/2011/275617</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/275617</ArticleId><ArticleId IdType="pmc">PMC3206376</ArticleId><ArticleId IdType="pubmed">22121373</ArticleId></ArticleIdList></Reference><Reference><Citation>Brkic Z, van Bon L, Cossu M, et al. . The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis 2016;75:1567&#x2013;73. 10.1136/annrheumdis-2015-207392</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207392</ArticleId><ArticleId IdType="pubmed">26371289</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Higgs BW, Chang L, et al. . Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-&#x3b1; receptor antibody. Clin Pharmacol Ther 2013;93:483&#x2013;92. 10.1038/clpt.2013.35</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.35</ArticleId><ArticleId IdType="pubmed">23511714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding W, Pu W, Wang L, et al. . Genome-wide DNA methylation analysis in systemic sclerosis reveals hypomethylation of IFN-associated genes in CD4+ and CD8+ T cells. J Invest Dermatol 2018;138:1069&#x2013;77. 10.1016/j.jid.2017.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2017.12.003</ArticleId><ArticleId IdType="pubmed">29248544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuttge DM, Lood C, Tufvesson E, et al. . Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sj&#xf6;gren&#x2019;s syndrome antigens and nuclear ribonucleoprotein antigens. Scand J Rheumatol 2013;42:235&#x2013;40. 10.3109/03009742.2012.736532</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2012.736532</ArticleId><ArticleId IdType="pubmed">23379597</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun WC, Sun YC, Lin H, et al. . Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol 2012;167:1236&#x2013;44. 10.1111/j.1365-2133.2012.11145.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2012.11145.x</ArticleId><ArticleId IdType="pubmed">23013528</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao AP, Salajegheh M, Nazareno R, et al. . Interferon &#x3b2; is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2011;70:831&#x2013;6. 10.1136/ard.2010.139949</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.139949</ArticleId><ArticleId IdType="pubmed">21177291</ArticleId></ArticleIdList></Reference><Reference><Citation>Horai Y, Koga T, Fujikawa K, et al. . Serum interferon-&#x3b1; is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol 2015;25:85&#x2013;9. 10.3109/14397595.2014.900843</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14397595.2014.900843</ArticleId><ArticleId IdType="pubmed">24716595</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SA, Higgs BW, Morehouse C, et al. . Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 2012;13:207&#x2013;13. 10.1038/gene.2011.61</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gene.2011.61</ArticleId><ArticleId IdType="pubmed">21881594</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh RJ, Kong SW, Yao Y, et al. . Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784&#x2013;92. 10.1002/art.22928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22928</ArticleId><ArticleId IdType="pmc">PMC2443782</ArticleId><ArticleId IdType="pubmed">17968926</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor KA, Abbott KA, Sabin B, et al. . Mxa gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006;120:319&#x2013;25. 10.1016/j.clim.2006.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2006.05.011</ArticleId><ArticleId IdType="pmc">PMC3163162</ArticleId><ArticleId IdType="pubmed">16859997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgic H, Ytterberg SR, Amin S, et al. . Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60:3436&#x2013;46. 10.1002/art.24936</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24936</ArticleId><ArticleId IdType="pubmed">19877033</ArticleId></ArticleIdList></Reference><Reference><Citation>Piper CJM, Wilkinson MGLl, Deakin CT, et al. . CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-&#x3b1;. Front Immunol 2018;9:1372. 10.3389/fimmu.2018.01372</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01372</ArticleId><ArticleId IdType="pmc">PMC6024011</ArticleId><ArticleId IdType="pubmed">29988398</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold TB, Kariuki SN, Morgan GA, et al. . Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009;60:1815&#x2013;24. 10.1002/art.24555</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24555</ArticleId><ArticleId IdType="pmc">PMC2697261</ArticleId><ArticleId IdType="pubmed">19479879</ArticleId></ArticleIdList></Reference><Reference><Citation>Balboni I, Niewold TB, Morgan G, et al. . Interferon-&#x391; induction and detection of anti-Ro, Anti-La, anti-Sm, and anti-RNP autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum 2013;65:2424&#x2013;9. 10.1002/art.38038</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38038</ArticleId><ArticleId IdType="pmc">PMC4169271</ArticleId><ArticleId IdType="pubmed">23740815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekholm L, Vosslamber S, Tj&#xe4;rnlund A, et al. . Autoantibody specificities and type I interferon pathway activation in idiopathic inflammatory myopathies. Scand J Immunol 2016;84:100&#x2013;9. 10.1111/sji.12449</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12449</ArticleId><ArticleId IdType="pubmed">27173897</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenn RC, Yalavarthi S, Gandhi AA, et al. . Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. Ann Rheum Dis 2017;76:450&#x2013;7. 10.1136/annrheumdis-2016-209442</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209442</ArticleId><ArticleId IdType="pmc">PMC5233467</ArticleId><ArticleId IdType="pubmed">27432357</ArticleId></ArticleIdList></Reference><Reference><Citation>Palli E, Kravvariti E, Tektonidou MG. Type I interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations. Front Immunol 2019;10:487. 10.3389/fimmu.2019.00487</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00487</ArticleId><ArticleId IdType="pmc">PMC6428719</ArticleId><ArticleId IdType="pubmed">30930907</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugolini-Lopes MR, Torrezan GT, G&#xe2;ndara APR, et al. . Enhanced type I interferon gene signature in primary antiphospholipid syndrome: association with earlier disease onset and preeclampsia. Autoimmun Rev 2019;18:393&#x2013;8. 10.1016/j.autrev.2018.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.11.004</ArticleId><ArticleId IdType="pubmed">30772492</ArticleId></ArticleIdList></Reference><Reference><Citation>Puccetti A, Fiore PF, Pelosi A, et al. . Gene expression profiling in behcet&#x2019;s disease indicates an autoimmune component in the pathogenesis of the disease and opens new avenues for targeted therapy. J Immunol Res 2018;2018:4246965. 10.1155/2018/4246965</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4246965</ArticleId><ArticleId IdType="pmc">PMC5941805</ArticleId><ArticleId IdType="pubmed">29850627</ArticleId></ArticleIdList></Reference><Reference><Citation>Pay S, Simsek I, Erdem H, et al. . Dendritic cell subsets and type I interferon system in beh&#xe7;et&#x2019;s disease: does functional abnormality in plasmacytoid dendritic cells contribute to th1 polarization? Clin Exp Rheumatol 2007;25:S34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17949549</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz S, Cinar M, Pekel A, et al. . The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with beh&#xe7;et&#x2019;s disease. Clin Exp Rheumatol 2013;31:84&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24064021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MT, Hooper LC, Kump L, et al. . Interferon-Beta and adhesion molecules (E-selectin and s-intracellular adhesion molecule-1) are detected in sera from patients with retinal vasculitis and are induced in retinal vascular endothelial cells by Toll-like receptor 3 signalling. Clin Exp Immunol 2007;147:71&#x2013;80. 10.1111/j.1365-2249.2006.03253.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2006.03253.x</ArticleId><ArticleId IdType="pmc">PMC1810441</ArticleId><ArticleId IdType="pubmed">17177965</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan JJ, Xing GQ. Pathogenesis of antimicrobial peptides LL-37 and cpg-ODN in ANCA associated vasculitis. J Nephrol 2017;30:63&#x2013;71. 10.1007/s40620-016-0336-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-016-0336-z</ArticleId><ArticleId IdType="pubmed">27476166</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Shi W, Tang S, et al. . The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA) -associated vasculitis. Arthritis Res Ther 2013;15:R161. 10.1186/ar4344</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4344</ArticleId><ArticleId IdType="pmc">PMC3979017</ArticleId><ArticleId IdType="pubmed">24286516</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Wang X, Zheng Y. Screening for key genes and transcription factors in ankylosing spondylitis by RNA-seq. Exp Ther Med 2018;15:1394&#x2013;402. 10.3892/etm.2017.5556</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2017.5556</ArticleId><ArticleId IdType="pmc">PMC5774495</ArticleId><ArticleId IdType="pubmed">29434723</ArticleId></ArticleIdList></Reference><Reference><Citation>De Andrea M, De Santis M, Caneparo V, et al. . Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis. Clin Exp Immunol 2020;199:88&#x2013;96. 10.1111/cei.13376</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13376</ArticleId><ArticleId IdType="pmc">PMC6904656</ArticleId><ArticleId IdType="pubmed">31571199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Takano K, Kamekura R, et al. . Stage classification of IgG4-related Dacryoadenitis and sialadenitis by the serum cytokine environment. Mod Rheumatol 2018;28:1004&#x2013;8. 10.1080/14397595.2018.1436029</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2018.1436029</ArticleId><ArticleId IdType="pubmed">29385874</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson AA, Sturfelt G, Truedsson L, et al. . Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664&#x2013;71. 10.1191/096120300674499064</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120300674499064</ArticleId><ArticleId IdType="pubmed">11199920</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf6;nsen A, Bengtsson AA, Nived O, et al. . The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus 2003;12:846&#x2013;50. 10.1191/0961203303lu472sr</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu472sr</ArticleId><ArticleId IdType="pubmed">14667101</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose T, Gr&#xfc;tzkau A, Hirseland H, et al. . Ifn&#x3b1; and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 2013;72:1639&#x2013;45. 10.1136/annrheumdis-2012-201586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201586</ArticleId><ArticleId IdType="pubmed">23117242</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose T, Gr&#xfc;tzkau A, Klotsche J, et al. . Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology (Oxford) 2017;56:1618&#x2013;26. 10.1093/rheumatology/kex220</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex220</ArticleId><ArticleId IdType="pubmed">28859328</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider L, Colar da Silva AC, Werres Junior LC, et al. . Vitamin D levels and cytokine profiles in patients with systemic lupus erythematosus. Lupus 2015;24:1191&#x2013;7. 10.1177/0961203315584811</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315584811</ArticleId><ArticleId IdType="pubmed">25926056</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V, Gunnarsson I, Dorschner J, et al. . High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther 2019;21:107. 10.1186/s13075-019-1878-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1878-y</ArticleId><ArticleId IdType="pmc">PMC6489203</ArticleId><ArticleId IdType="pubmed">31036046</ArticleId></ArticleIdList></Reference><Reference><Citation>Munroe ME, Vista ES, Merrill JT, et al. . Pathways of impending disease flare in african-american systemic lupus erythematosus patients. J Autoimmun 2017;78:70&#x2013;8. 10.1016/j.jaut.2016.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.12.005</ArticleId><ArticleId IdType="pmc">PMC5340190</ArticleId><ArticleId IdType="pubmed">28162788</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer JW, Baechler EC, Petri M, et al. . Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006;3:e491. 10.1371/journal.pmed.0030491</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030491</ArticleId><ArticleId IdType="pmc">PMC1702557</ArticleId><ArticleId IdType="pubmed">17177599</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer JW, Petri M, Batliwalla FM, et al. . Interferon-Regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009;60:3098&#x2013;107. 10.1002/art.24803</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24803</ArticleId><ArticleId IdType="pmc">PMC2842939</ArticleId><ArticleId IdType="pubmed">19790071</ArticleId></ArticleIdList></Reference><Reference><Citation>Connelly KL, Kandane-Rathnayake R, Hoi A, et al. . Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in asian patients with systemic lupus erythematosus. Sci Rep 2016;6:29909. 10.1038/srep29909</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep29909</ArticleId><ArticleId IdType="pmc">PMC4958969</ArticleId><ArticleId IdType="pubmed">27453287</ArticleId></ArticleIdList></Reference><Reference><Citation>Connelly KL, Kandane-Rathnayake R, Huq M, et al. . Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. Sci Rep 2018;8:3268. 10.1038/s41598-018-20203-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-20203-9</ArticleId><ArticleId IdType="pmc">PMC5818532</ArticleId><ArticleId IdType="pubmed">29459655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-R, Haddon DJ, Wand HE, et al. . Multiplex giant magnetoresistive biosensor microarrays identify interferon-associated autoantibodies in systemic lupus erythematosus. Sci Rep 2016;6:27623. 10.1038/srep27623</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep27623</ArticleId><ArticleId IdType="pmc">PMC4899742</ArticleId><ArticleId IdType="pubmed">27279139</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki M, Fujishiro M, Yamaguchi A, et al. . Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus. Lupus 2011;20:1231&#x2013;9. 10.1177/0961203311409963</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311409963</ArticleId><ArticleId IdType="pubmed">21980035</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikpour M, Dempsey AA, Urowitz MB, et al. . Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 2008;67:1069&#x2013;75. 10.1136/ard.2007.074765</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2007.074765</ArticleId><ArticleId IdType="pubmed">18063674</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Jin Z, Rosenzweig E, et al. . Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. J Autoimmun 2015;60:51&#x2013;8. 10.1016/j.jaut.2015.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.04.002</ArticleId><ArticleId IdType="pmc">PMC4457613</ArticleId><ArticleId IdType="pubmed">25921064</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Immermann F, Whitley M, et al. . The biomarkers of lupus disease study: A bold approach may mitigate interference of background immunosuppressants in clinical trials. Arthritis Rheumatol 2017;69:1257&#x2013;66. 10.1002/art.40086</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40086</ArticleId><ArticleId IdType="pmc">PMC5501389</ArticleId><ArticleId IdType="pubmed">28257602</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich SA, Owens TR, Anzola MC, et al. . Induction of lupus inclusions by sera from patients with systemic lupus erythematosus. Arthritis Rheum 1986;29:501&#x2013;7. 10.1002/art.1780290407</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780290407</ArticleId><ArticleId IdType="pubmed">3486663</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Singh S, Tesfasyone H, et al. . Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009;18:980&#x2013;9. 10.1177/0961203309105529</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309105529</ArticleId><ArticleId IdType="pmc">PMC4752166</ArticleId><ArticleId IdType="pubmed">19762399</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantaert T, van Baarsen LG, Wijbrandts CA, et al. . Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology (Oxford) 2010;49:156&#x2013;66. 10.1093/rheumatology/kep345</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep345</ArticleId><ArticleId IdType="pubmed">19933783</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurlings RM, Boumans M, Tekstra J, et al. . Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010;62:3607&#x2013;14. 10.1002/art.27702</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27702</ArticleId><ArticleId IdType="pubmed">20722020</ArticleId></ArticleIdList></Reference><Reference><Citation>James JA, Guthridge JM, Chen H, et al. . Unique Sj&#xf6;gren&#x2019;s syndrome patient subsets defined by molecular features. Rheumatology (Oxford) 2020;59:860&#x2013;8. 10.1093/rheumatology/kez335</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez335</ArticleId><ArticleId IdType="pmc">PMC7188221</ArticleId><ArticleId IdType="pubmed">31497844</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson P, Bodewes ILA, Nilsson AM, et al. . Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sj&#xf6;gren&#x2019;s syndrome. Rheumatol Int 2019;39:1575&#x2013;84. 10.1007/s00296-019-04335-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04335-3</ArticleId><ArticleId IdType="pubmed">31139950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xf3;l P, Kry&#x161;t&#x16f;fkov&#xe1; O, Polansk&#xe1; M, et al. . Serum levels of interferon &#x3b1; do not correlate with disease activity in patients with dermatomyositis/polymyositis. Ann Rheum Dis 2011;70:879&#x2013;80. 10.1136/ard.2010.141051</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.141051</ArticleId><ArticleId IdType="pubmed">21068097</ArticleId></ArticleIdList></Reference><Reference><Citation>Huard C, Gull&#xe0; SV, Bennett DV, et al. . Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon &#x3b2; in dermatomyositis. Br J Dermatol 2017;176:1224&#x2013;30. 10.1111/bjd.15006</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.15006</ArticleId><ArticleId IdType="pubmed">27564228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Mouries-Martin S, Dorgham K, et al. . Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital enzyme-linked immunosorbent assay quantification of serum interferon-&#x3b1;. Arthritis Rheumatol 2019;71:756&#x2013;65. 10.1002/art.40792</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40792</ArticleId><ArticleId IdType="pubmed">30507062</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiman AJ, Gladman DD, Iba&#xf1;ez D, et al. . Lack of interferon and proinflammatory cyto/chemokines in serologically active clinically quiescent systemic lupus erythematosus. J Rheumatol 2015;42:2318&#x2013;26. 10.3899/jrheum.150040</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.150040</ArticleId><ArticleId IdType="pubmed">26568589</ArticleId></ArticleIdList></Reference><Reference><Citation>van Baarsen LG, Wijbrandts CA, Rustenburg F, et al. . Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010;12:R11. 10.1186/ar2912</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2912</ArticleId><ArticleId IdType="pmc">PMC2875639</ArticleId><ArticleId IdType="pubmed">20096109</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;bbers J, Brink M, van de Stadt LA, et al. . The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis 2013;72:776&#x2013;80. 10.1136/annrheumdis-2012-202753</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202753</ArticleId><ArticleId IdType="pubmed">23434571</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, et al. . Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376&#x2013;86. 10.1002/art.39962</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalunian KC, Merrill JT, Maciuca R, et al. . A phase II study of the efficacy and safety of rontalizumab (rhumab interferon-&#x3b1;) in patients with systemic lupus erythematosus (rose). Ann Rheum Dis 2016;75:196&#x2013;202. 10.1136/annrheumdis-2014-206090</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206090</ArticleId><ArticleId IdType="pubmed">26038091</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Furie R, Werth VP, et al. . Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med 2018;5:e000284. 10.1136/lupus-2018-000284</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000284</ArticleId><ArticleId IdType="pmc">PMC6280909</ArticleId><ArticleId IdType="pubmed">30588322</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Wallace DJ, Spindler A, et al. . Sifalimumab, a human anti-interferon-&#x3b1; monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65:1011&#x2013;21. 10.1002/art.37824</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37824</ArticleId><ArticleId IdType="pmc">PMC3654174</ArticleId><ArticleId IdType="pubmed">23400715</ArticleId></ArticleIdList></Reference><Reference><Citation>Vosslamber S, Raterman HG, van der Pouw Kraan TCTM, et al. . Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 2011;70:1153&#x2013;9. 10.1136/ard.2010.147199</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.147199</ArticleId><ArticleId IdType="pubmed">21444302</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanayama Y, Ikeda K, Saito Y, et al. . Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheumatol 2014;66:1421&#x2013;31. 10.1002/art.38400</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38400</ArticleId><ArticleId IdType="pubmed">24591094</ArticleId></ArticleIdList></Reference><Reference><Citation>Raterman HG, Vosslamber S, de Ridder S, et al. . The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012;14:R95. 10.1186/ar3819</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3819</ArticleId><ArticleId IdType="pmc">PMC3446469</ArticleId><ArticleId IdType="pubmed">22540992</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong TD, Vosslamber S, Blits M, et al. . Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Arthritis Res Ther 2015;17:78. 10.1186/s13075-015-0564-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0564-y</ArticleId><ArticleId IdType="pmc">PMC4416246</ArticleId><ArticleId IdType="pubmed">25889713</ArticleId></ArticleIdList></Reference><Reference><Citation>Wampler Muskardin T, Vashisht P, Dorschner JM, et al. . Increased pretreatment serum IFN-&#x3b2;/&#x3b1; ratio predicts non-response to tumour necrosis factor &#x3b1; inhibition in rheumatoid arthritis. Ann Rheum Dis 2016;75:1757&#x2013;62. 10.1136/annrheumdis-2015-208001</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208001</ArticleId><ArticleId IdType="pmc">PMC4860184</ArticleId><ArticleId IdType="pubmed">26546586</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed AM, Peterson E, Bilgic H, et al. . Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 2012;64:4078&#x2013;86. 10.1002/art.34659</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34659</ArticleId><ArticleId IdType="pmc">PMC3510329</ArticleId><ArticleId IdType="pubmed">22886447</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed AM, Crowson CS, Hein M, et al. . Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord 2015;16:257. 10.1186/s12891-015-0710-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-015-0710-3</ArticleId><ArticleId IdType="pmc">PMC4574570</ArticleId><ArticleId IdType="pubmed">26382217</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartuccio L, Mavragani CP, Nezos A, et al. . Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sj&#xf6;gren&#x2019;s syndrome. Clin Exp Rheumatol 2017;35:719&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">28281461</ArticleId></ArticleIdList></Reference><Reference><Citation>Aranow C, Kamen DL, Dall&#x2019;Era M, et al. . Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus. Arthritis Rheumatol 2015;67:1848&#x2013;57. 10.1002/art.39108</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39108</ArticleId><ArticleId IdType="pmc">PMC4732716</ArticleId><ArticleId IdType="pubmed">25777546</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasni S, Gupta S, Davis M, et al. . Safety and tolerability of omalizumab: a randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1135&#x2013;40. 10.1002/art.40828</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40828</ArticleId><ArticleId IdType="pmc">PMC6594871</ArticleId><ArticleId IdType="pubmed">30597768</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride JM, Jiang J, Abbas AR, et al. . Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012;64:3666&#x2013;76. 10.1002/art.34632</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34632</ArticleId><ArticleId IdType="pubmed">22833362</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Wallace DJ, Petri M, et al. . Safety profile and clinical activity of sifalimumab, a fully human anti-interferon &#x3b1; monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;70:1905&#x2013;13. 10.1136/ard.2010.144485</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.144485</ArticleId><ArticleId IdType="pubmed">21798883</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Sarfert R, Klotsche J, et al. . The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015;74:1474&#x2013;8. 10.1136/annrheumdis-2014-206016</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206016</ArticleId><ArticleId IdType="pmc">PMC4484251</ArticleId><ArticleId IdType="pubmed">25710470</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Fu W, Ranger A, et al. . Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Med Genomics 2019;12:4. 10.1186/s12920-018-0468-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-018-0468-1</ArticleId><ArticleId IdType="pmc">PMC6327466</ArticleId><ArticleId IdType="pubmed">30626389</ArticleId></ArticleIdList></Reference><Reference><Citation>von Wussow P, Jakschies D, Hartung K, et al. . Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int 1988;8:225&#x2013;30. 10.1007/BF00269199</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00269199</ArticleId><ArticleId IdType="pubmed">3266358</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartier P, Allantaz F, Cimaz R, et al. . A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747&#x2013;54. 10.1136/ard.2010.134254</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.134254</ArticleId><ArticleId IdType="pmc">PMC3070271</ArticleId><ArticleId IdType="pubmed">21173013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienkowska J, Allaire N, Thai A, et al. . Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS ONE 2014;9:e112545. 10.1371/journal.pone.0112545</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0112545</ArticleId><ArticleId IdType="pmc">PMC4236099</ArticleId><ArticleId IdType="pubmed">25405351</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez De Padilla CM, Crowson CS, Hein MS, et al. . Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. Clin Exp Rheumatol 2015;33:655&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">26446265</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgs BW, Zhu W, Morehouse C, et al. . A phase 1B clinical trial evaluating sifalimumab, an anti-IFN-&#x3b1; monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014;73:256&#x2013;62. 10.1136/annrheumdis-2012-202794</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202794</ArticleId><ArticleId IdType="pmc">PMC3888620</ArticleId><ArticleId IdType="pubmed">23434567</ArticleId></ArticleIdList></Reference><Reference><Citation>Dastmalchi M, Grundtman C, Alexanderson H, et al. . A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670&#x2013;7. 10.1136/ard.2007.077974</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2007.077974</ArticleId><ArticleId IdType="pubmed">18272672</ArticleId></ArticleIdList></Reference><Reference><Citation>McNab F, Mayer-Barber K, Sher A, et al. . Type I interferons in infectious disease. Nat Rev Immunol 2015;15:87&#x2013;103. 10.1038/nri3787</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3787</ArticleId><ArticleId IdType="pmc">PMC7162685</ArticleId><ArticleId IdType="pubmed">25614319</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuertes MB, Woo S-R, Burnett B, et al. . Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013;34:67&#x2013;73. 10.1016/j.it.2012.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2012.10.004</ArticleId><ArticleId IdType="pmc">PMC3565059</ArticleId><ArticleId IdType="pubmed">23122052</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H-J, Tas SW, de Winther MPJ. Type-I interferons in atherosclerosis. J Exp Med 2020;217:e20190459. 10.1084/jem.20190459</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190459</ArticleId><ArticleId IdType="pmc">PMC7037237</ArticleId><ArticleId IdType="pubmed">31821440</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahadat MJ, Schonenberg-Meinema D, van Helden-Meeuwsen CG, et al. . Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study. Rheumatology (Oxford) 2022;61:4344&#x2013;54. 10.1093/rheumatology/keac083</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac083</ArticleId><ArticleId IdType="pmc">PMC9629374</ArticleId><ArticleId IdType="pubmed">35143620</ArticleId></ArticleIdList></Reference><Reference><Citation>Northcott M, Gearing LJ, Bonin J, et al. . Immunosuppressant exposure confounds gene expression analysis in systemic lupus erythematosus. Front Immunol 2022;13:964263. 10.3389/fimmu.2022.964263</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.964263</ArticleId><ArticleId IdType="pmc">PMC9430375</ArticleId><ArticleId IdType="pubmed">36059457</ArticleId></ArticleIdList></Reference><Reference><Citation>Omdal R, Mellgren SI, Koldingsnes W, et al. . Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 2002;29:482&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11908560</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies K, Mirza K, Tarn J, et al. . Fatigue in primary Sj&#xf6;gren&#x2019;s syndrome (PSS) is associated with lower levels of proinflammatory cytokines: a validation study. Rheumatol Int 2019;39:1867&#x2013;73. 10.1007/s00296-019-04354-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04354-0</ArticleId><ArticleId IdType="pmc">PMC6791914</ArticleId><ArticleId IdType="pubmed">31250166</ArticleId></ArticleIdList></Reference><Reference><Citation>Prak RF, Arends S, Verstappen GM, et al. . Fatigue in primary Sj&#xf6;gren&#x2019;s syndrome is associated with an objective decline in physical performance, pain and depression. Clin Exp Rheumatol 2022;40:2318&#x2013;28. 10.55563/clinexprheumatol/70s6cs</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/70s6cs</ArticleId><ArticleId IdType="pubmed">36226629</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard Tripp N, Tarn J, Natasari A, et al. . Fatigue in primary Sj&#xf6;gren&#x2019;s syndrome is associated with lower levels of proinflammatory cytokines. RMD Open 2016;2:e000282. 10.1136/rmdopen-2016-000282</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2016-000282</ArticleId><ArticleId IdType="pmc">PMC4964201</ArticleId><ArticleId IdType="pubmed">27493792</ArticleId></ArticleIdList></Reference><Reference><Citation>Posada J, Valadkhan S, Burge D, et al. . Improvement of severe fatigue following nuclease therapy in patients with primary Sj&#xf6;gren&#x2019;s syndrome: a randomized clinical trial. Arthritis Rheumatol 2021;73:143&#x2013;50. 10.1002/art.41489</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41489</ArticleId><ArticleId IdType="pmc">PMC7839752</ArticleId><ArticleId IdType="pubmed">32798283</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins A, Lendrem D, Wason J, et al. . Revisiting the JOQUER trial: stratification of primary Sj&#xf6;gren&#x2019;s syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatol Int 2021;41:1593&#x2013;600. 10.1007/s00296-021-04927-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04927-y</ArticleId><ArticleId IdType="pmc">PMC8316226</ArticleId><ArticleId IdType="pubmed">34165604</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, et al. . Systemic interferon type I and type II signatures in primary Sj&#xf6;gren&#x2019;s syndrome reveal differences in biological disease activity. Rheumatology (Oxford) 2018;57:921&#x2013;30. 10.1093/rheumatology/kex490</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex490</ArticleId><ArticleId IdType="pubmed">29474655</ArticleId></ArticleIdList></Reference><Reference><Citation>Vital EM, Merrill JT, Morand EF, et al. . Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis 2022;81:951&#x2013;61. 10.1136/annrheumdis-2021-221425</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221425</ArticleId><ArticleId IdType="pmc">PMC9213795</ArticleId><ArticleId IdType="pubmed">35338035</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsky PE, Vollenhoven R van, D&#xf6;rner T, et al. . Biological impact of iberdomide in patients with active systemic lupus erythematosus. Ann Rheum Dis 2022;81:1136&#x2013;42. 10.1136/annrheumdis-2022-222212</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222212</ArticleId><ArticleId IdType="pmc">PMC9279852</ArticleId><ArticleId IdType="pubmed">35477518</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>